Paravertebral Block for Mastectomy with Immediate Reconstruction

Last updated: March 5, 2025
Sponsor: CHU de Quebec-Universite Laval
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pain

Acute Pain

Chronic Pain

Treatment

Paravertebral block

Usual analgesia

Clinical Study ID

NCT06276257
2024-7301
  • Ages 18-70
  • Female

Study Summary

Following a mastectomy, patients may develop chronic pain, called post-mastectomy pain syndrome (PMPS). This syndrome manifests itself as complex neuropathic pain that seems linked to nerve damage suffered either during surgery, during healing or by nervous system dysfunction. However, the exact pathophysiology remains unknown. Typically, the pain is located on the ipsilateral side of the surgery and projects to the anterior thorax to the lateral thorax and may affect the proximal part of the arm. This pain persists for more than three months following the procedure and has the characteristics of neuropathic pain: burning sensation, tingling, electric shock, hyperalgesia, etc. The prevalence of PMDS varies between 2% and 78%; this disparity comes from the fact that there are no clear criteria in the literature for making the diagnosis. One of the risk factors for developing PMDS is the presence of acute pain immediately postoperatively.

The main objective of this study is to compare two analgesic modalities, namely BPV (study modality) and usual analgesia (control modality), in patients undergoing total mastectomy with immediate reconstruction under general anesthesia with the aim of to evaluate their functional pain score at 24, 48 and 72 hours following the surgical procedure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-70 years of age

  • woman scheduled for unilateral mastectomy with immediate reconstruction

Exclusion

Exclusion Criteria:

  • Patients who will have an axillary dissection during surgery.

  • Woman with severe hepatic insufficiency (Child Pugh Classification B and above24).

  • Woman with kidney failure stage 4 and above25.

  • Body mass index (BMI) > 40 kg/m2.

  • Woman with an allergy to local anesthetics.

  • Woman with a bleeding disorder in whom BPV is contraindicated.

  • Woman in whom stopping antiplatelet or anticoagulant therapy does not allowcompliance with the standards of practice of neuraxial anesthesia issued by theAmerican Society of Regional Anesthesia.

  • Woman with a single lung.

  • Pregnant woman.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Paravertebral block
Phase:
Study Start date:
August 05, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • CHU de Quebec - Universite Laval

    Quebec City, Quebec G1H5B8
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.